{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:54:13Z","timestamp":1794020053723,"version":"4.8.0"},"reference-count":147,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["FB GNT2016841"],"award-info":[{"award-number":["FB GNT2016841"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Immunology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.smim.2025.101944","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T03:40:43Z","timestamp":1741923643000},"page":"101944","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Insights into pathogenesis and biomarkers of prognosis"],"prefix":"10.1016","volume":"78","author":[{"given":"Jane","family":"Andersen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7025-2276","authenticated-orcid":false,"given":"Fabienne","family":"Brilot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.smim.2025.101944_bib1","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0896-8411(89)90149-2","article-title":"Chronic experimental autoimmune encephalomyelitis in the guinea pig. Presence of anti-M2 antibodies in central nervous system tissue and the possible role of M2 autoantigen in the induction of the disease","volume":"2","author":"Lebar","year":"1989","journal-title":"J. Autoimmun."},{"issue":"6","key":"10.1016\/j.smim.2025.101944_bib2","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1172\/JCI118368","article-title":"Antibody facilitation of multiple sclerosis-like lesions in a nonhuman primate","volume":"96","author":"Genain","year":"1995","journal-title":"J. Clin. Invest"},{"issue":"3","key":"10.1016\/j.smim.2025.101944_bib3","first-page":"443","article-title":"Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin\/oligodendrocyte glycoprotein","volume":"130","author":"Linington","year":"1988","journal-title":"Am. J. Pathol."},{"issue":"2","key":"10.1016\/j.smim.2025.101944_bib4","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00401-016-1631-4","article-title":"Multiple sclerosis: experimental models and reality","volume":"133","author":"Lassmann","year":"2017","journal-title":"Acta Neuropathol."},{"issue":"2","key":"10.1016\/j.smim.2025.101944_bib5","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/5532","article-title":"Identification of autoantibodies associated with myelin damage in multiple sclerosis","volume":"5","author":"Genain","year":"1999","journal-title":"Nat. Med"},{"issue":"2","key":"10.1016\/j.smim.2025.101944_bib6","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1056\/NEJMoa022328","article-title":"Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event","volume":"349","author":"Berger","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"Pt 3","key":"10.1016\/j.smim.2025.101944_bib7","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/brain\/121.3.495","article-title":"The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up","volume":"121","author":"O'Riordan","year":"1998","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.smim.2025.101944_bib8","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1191\/1352458505ms1187sr","article-title":"Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis","volume":"11","author":"Lim","year":"2005","journal-title":"Mult. Scler."},{"issue":"4","key":"10.1016\/j.smim.2025.101944_bib9","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMc062467","article-title":"Antimyelin antibodies with no progression to multiple sclerosis","volume":"356","author":"Pelayo","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.smim.2025.101944_bib10","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1056\/NEJMoa063602","article-title":"Lack of association between antimyelin antibodies and progression to multiple sclerosis","volume":"356","author":"Kuhle","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.smim.2025.101944_bib11","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1136\/jnnp.2005.077784","article-title":"Antimyelin antibodies and the risk of relapse in patients with a primary demyelinating event","volume":"77","author":"Rauer","year":"2006","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"15","key":"10.1016\/j.smim.2025.101944_bib12","first-page":"1142","article-title":"Myelin oligodendrocyte glycoprotein antibodies and multiple sclerosis in healthy young adults","volume":"71","author":"Wang","year":"2008","journal-title":"Symb. Neurol."},{"issue":"1","key":"10.1016\/j.smim.2025.101944_bib13","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/1352458506072189","article-title":"Myelin oligodendrocyte glycoprotein antibodies in pathologically proven multiple sclerosis: frequency, stability and clinicopathologic correlations","volume":"13","author":"Pittock","year":"2007","journal-title":"Mult. Scler."},{"issue":"1-2","key":"10.1016\/j.smim.2025.101944_bib14","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jneuroim.2006.01.012","article-title":"Epitope specificity of serum antibodies directed against the extracellular domain of myelin oligodendrocyte glycoprotein: influence of relapses and immunomodulatory treatments","volume":"174","author":"Khalil","year":"2006","journal-title":"J. Neuroimmunol."},{"issue":"2","key":"10.1016\/j.smim.2025.101944_bib15","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nm1488","article-title":"Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein","volume":"13","author":"O'Connor","year":"2007","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.smim.2025.101944_bib16","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000089","article-title":"MOG cell-based assay detects non-MS patients with inflammatory neurologic disease","volume":"2","author":"Waters","year":"2015","journal-title":"Neurol. - Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.smim.2025.101944_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.101939","article-title":"Refining cell-based assay to detect MOG-IgG in patients with central nervous system inflammatory diseases","volume":"40","author":"Kim","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"11","key":"10.1016\/j.smim.2025.101944_bib18","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000007096","article-title":"A multicenter comparison of MOG-IgG cell-based assays","volume":"92","author":"Waters","year":"2019","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.smim.2025.101944_bib19","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S1474-4422(19)30244-3","article-title":"An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models","volume":"18","author":"Dalmau","year":"2019","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.smim.2025.101944_bib20","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000674","article-title":"International multicenter examination of MOG antibody assays","volume":"7","author":"Reindl","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"1","key":"10.1016\/j.smim.2025.101944_bib21","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s40478-019-0786-3","article-title":"Australasian; New Zealand, M. O. G. S. G., Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination","volume":"7","author":"Tea","year":"2019","journal-title":"Acta Neuropathol. Commun."},{"issue":"8","key":"10.1016\/j.smim.2025.101944_bib22","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/brain\/awab105","article-title":"Features of MOG required for recognition by patients with MOG antibody-associated disorders","volume":"144","author":"Macrini","year":"2021","journal-title":"Brain"},{"issue":"6","key":"10.1016\/j.smim.2025.101944_bib23","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/ana.21916","article-title":"Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease","volume":"66","author":"Brilot","year":"2009","journal-title":"Ann. Neurol."},{"issue":"12","key":"10.1016\/j.smim.2025.101944_bib24","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1212\/WNL.0b013e31826aac4e","article-title":"Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype","volume":"79","author":"Kitley","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.smim.2025.101944_bib25","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/1742-2094-8-184","article-title":"Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders","volume":"8","author":"Mader","year":"2011","journal-title":"J. Neuroinflamm."},{"issue":"3","key":"10.1016\/j.smim.2025.101944_bib26","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.smim.2025.101944_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2024.103693","article-title":"MOGAD: a comprehensive review of clinicoradiological features, therapy and outcomes in 4699 patients globally","volume":"24","author":"Trewin","year":"2025","journal-title":"Autoimmun. Rev."},{"issue":"10","key":"10.1016\/j.smim.2025.101944_bib28","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1136\/jnnp-2020-323158","article-title":"Prevalence and incidence of neuromyelitis optica spectrum disorder, aquaporin-4 antibody-positive NMOSD and MOG antibody-positive disease in Oxfordshire, UK","volume":"91","author":"O'Connell","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"7","key":"10.1016\/j.smim.2025.101944_bib29","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1177\/1352458519845112","article-title":"The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults","volume":"26","author":"de Mol","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.smim.2025.101944_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577742","article-title":"Clinicoradiological comparative study of Aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody associated disease (MOGAD): a prospective observational study and review of literature","volume":"361","author":"Nagireddy","year":"2021","journal-title":"J. Neuroimmunol."},{"issue":"21","key":"10.1016\/j.smim.2025.101944_bib31","doi-asserted-by":"crossref","first-page":"e1858","DOI":"10.1212\/WNL.0000000000005560","article-title":"Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study","volume":"90","author":"Cobo-Calvo","year":"2018","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.smim.2025.101944_bib32","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"issue":"11","key":"10.1016\/j.smim.2025.101944_bib33","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-055392","article-title":"Predictors of relapse in MOG antibody associated disease: a cohort study","volume":"11","author":"Huda","year":"2021","journal-title":"Bmj Open"},{"issue":"3","key":"10.1016\/j.smim.2025.101944_bib34","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/ene.12898","article-title":"Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands","volume":"23","author":"van Pelt","year":"2016","journal-title":"Eur. J. Neurol."},{"issue":"10","key":"10.1016\/j.smim.2025.101944_bib35","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.ophtha.2018.03.041","article-title":"Aquaporin-4 and myelin oligodendrocyte glycoprotein autoantibody status predict outcome of recurrent optic neuritis","volume":"125","author":"Jitprapaikulsan","year":"2018","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.smim.2025.101944_bib36","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00415-017-8651-4","article-title":"Clinical characteristics of myelin oligodendrocyte glycoprotein seropositive optic neuritis: a cohort study in Shanghai, China","volume":"265","author":"Zhao","year":"2018","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.smim.2025.101944_bib37","article-title":"Humoral signatures of MOG-antibody-associated disease track with age and disease activity","volume":"4","author":"Spatola","year":"2023","journal-title":"Cell Rep. Med."},{"issue":"13","key":"10.1016\/j.smim.2025.101944_bib38","first-page":"NP1","article-title":"The clinical course, therapeutic responses, and outcomes in relapsing MOG antibody-associated demyelination","volume":"23","author":"Ramanathan","year":"2017","journal-title":"Mult. Scler."},{"issue":"12","key":"10.1016\/j.smim.2025.101944_bib39","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1007\/s00415-017-8635-4","article-title":"Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study","volume":"264","author":"Mariotto","year":"2017","journal-title":"J. Neurol."},{"issue":"3","key":"10.1016\/j.smim.2025.101944_bib40","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1001\/jamaneurol.2018.4053","article-title":"Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody","volume":"76","author":"Dubey","year":"2019","journal-title":"JAMA Neurol."},{"issue":"9451","key":"10.1016\/j.smim.2025.101944_bib41","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.smim.2025.101944_bib42","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J. Exp. Med."},{"issue":"7","key":"10.1016\/j.smim.2025.101944_bib43","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1316","article-title":"Pathogenesis of autoimmune demyelination: from multiple sclerosis to neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"10","author":"Lopez","year":"2021","journal-title":"Clin. Transl. Immunol."},{"issue":"1","key":"10.1016\/j.smim.2025.101944_bib44","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1471-4159.1989.tb10930.x","article-title":"Differential ultrastructural localization of myelin basic protein, myelin\/oligodendroglial glycoprotein, and 2\u2032,3\u2032-cyclic nucleotide 3\u2032-phosphodiesterase in the CNS of adult rats","volume":"52","author":"Brunner","year":"1989","journal-title":"J. Neurochem."},{"issue":"1","key":"10.1016\/j.smim.2025.101944_bib45","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1046\/j.1471-4159.1995.65010309.x","article-title":"Characterization of cDNA and genomic clones encoding human myelin oligodendrocyte glycoprotein","volume":"65","author":"Hilton","year":"1995","journal-title":"J. Neurochem."},{"issue":"3","key":"10.1016\/j.smim.2025.101944_bib46","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0165-5728(89)90014-3","article-title":"Myelin-oligodendrocyte glycoprotein (MOG) is a surface marker of oligodendrocyte maturation","volume":"22","author":"Scolding","year":"1989","journal-title":"J. Neuroimmunol."},{"issue":"5","key":"10.1016\/j.smim.2025.101944_bib47","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1046\/j.1471-4159.1996.67052219.x","article-title":"Investigation of myelin\/oligodendrocyte glycoprotein membrane topology","volume":"67","author":"Kroepfl","year":"1996","journal-title":"J. Neurochem."},{"issue":"2","key":"10.1016\/j.smim.2025.101944_bib48","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000022","article-title":"Immunodominant T-cell epitopes of MOG reside in its transmembrane and cytoplasmic domains in EAE","volume":"1","author":"Shetty","year":"2014","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"13","key":"10.1016\/j.smim.2025.101944_bib49","doi-asserted-by":"crossref","first-page":"5461","DOI":"10.1523\/JNEUROSCI.23-13-05461.2003","article-title":"Antibody cross-linking of myelin oligodendrocyte glycoprotein leads to its rapid repartitioning into detergent-insoluble fractions, and altered protein phosphorylation and cell morphology","volume":"23","author":"Marta","year":"2003","journal-title":"J. Neurosci."},{"issue":"6","key":"10.1016\/j.smim.2025.101944_bib50","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1083\/jcb.201504106","article-title":"The myelin oligodendrocyte glycoprotein directly binds nerve growth factor to modulate central axon circuitry","volume":"210","author":"von B\u00fcdingen","year":"2015","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.smim.2025.101944_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2023.1014071","article-title":"Complement-dependent cytotoxicity of human autoantibodies against myelin oligodendrocyte glycoprotein","volume":"17","author":"Kohyama","year":"2023","journal-title":"Front. Neurosci."},{"issue":"7","key":"10.1016\/j.smim.2025.101944_bib52","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1007\/s00415-024-12285-5","article-title":"Improving the sensitivity of myelin oligodendrocyte glycoprotein-antibody testing: exclusive or predominant MOG-IgG3 seropositivity\u2014a potential diagnostic pitfall in patients with MOG-EM\/MOGAD","volume":"271","author":"Jarius","year":"2024","journal-title":"J. Neurol."},{"issue":"9","key":"10.1016\/j.smim.2025.101944_bib53","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1001\/jamaneurol.2023.2523","article-title":"Immunoglobulin A antibodies against myelin oligodendrocyte glycoprotein in a subgroup of patients with central nervous system demyelination","volume":"80","author":"Ayroza Galv\u00e3o Ribeiro Gomes","year":"2023","journal-title":"JAMA Neurol."},{"issue":"1","key":"10.1016\/j.smim.2025.101944_bib54","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/joim.13469","article-title":"Central nervous system zoning: how brain barriers establish subdivisions for CNS immune privilege and immune surveillance","volume":"292","author":"Proulx","year":"2022","journal-title":"J. Intern. Med."},{"issue":"5","key":"10.1016\/j.smim.2025.101944_bib55","article-title":"MOG CNS Autoimmunity and MOGAD","volume":"11","author":"Moseley","year":"2024","journal-title":"Neurol. Neuroimmunol. amp; Neuroinflamm."},{"issue":"4","key":"10.1016\/j.smim.2025.101944_bib56","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0198-8859(03)00027-2","article-title":"HLA types in celiac disease patients not carrying the DQA1*\u200905-DQB1*\u200902 (DQ2) heterodimer: results from the European Genetics Cluster on Celiac Disease","volume":"64","author":"Karell","year":"2003","journal-title":"Hum. Immunol."},{"issue":"2","key":"10.1016\/j.smim.2025.101944_bib57","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1399-0039.2007.00867.x","article-title":"Relative predispositional effects of HLA class II DRB1-DQB1 haplotypes and genotypes on type 1 diabetes: a meta-analysis","volume":"70","author":"Thomson","year":"2007","journal-title":"Tissue Antigens"},{"issue":"10","key":"10.1016\/j.smim.2025.101944_bib58","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/ng.3395","article-title":"Class II HLA interactions modulate genetic risk for multiple sclerosis","volume":"47","author":"Moutsianas","year":"2015","journal-title":"Nat. Genet."},{"issue":"7","key":"10.1016\/j.smim.2025.101944_bib59","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1136\/jnnp-2019-322115","article-title":"Myelin oligodendrocyte glycoprotein-associated disorders are associated with HLA subtypes in a Chinese paediatric-onset cohort","volume":"91","author":"Sun","year":"2020","journal-title":"J. Neurol., Neurosurg. Psychiatry"},{"issue":"3","key":"10.1016\/j.smim.2025.101944_bib60","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000702","article-title":"HLA association in MOG-IgG- and AQP4-IgG-related disorders of the CNS in the Dutch population","volume":"7","author":"Bruijstens","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"7","key":"10.1016\/j.smim.2025.101944_bib61","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1002\/acn3.51378","article-title":"No strong HLA association with MOG antibody disease in the UK population","volume":"8","author":"Grant-Peters","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"2","key":"10.1016\/j.smim.2025.101944_bib62","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000020","article-title":"MOG transmembrane and cytoplasmic domains contain highly stimulatory T-cell epitopes in MS","volume":"1","author":"Varrin-Doyer","year":"2014","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.smim.2025.101944_bib63","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01188","article-title":"Comparative Analysis of T-Cell Responses to Aquaporin-4 and myelin oligodendrocyte glycoprotein in inflammatory demyelinating central nervous system diseases","volume":"11","author":"Hofer","year":"2020","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.smim.2025.101944_bib64","first-page":"2416","article-title":"Autoantigen-specific CD4+\u2009T cells acquire an exhausted phenotype and persist in human antigen-specific autoimmune diseases","volume":"57","author":"Saggau","year":"2024","journal-title":"Immun. (Camb., Mass. )"},{"issue":"6","key":"10.1016\/j.smim.2025.101944_bib65","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1212\/NXI.0000000000000625","article-title":"Identification of circulating MOG-specific B cells in patients with MOG antibodies","volume":"6","author":"Winklmeier","year":"2019","journal-title":"Neurol. - Neuroimmunol. Neuroinflamm."},{"issue":"5","key":"10.1016\/j.smim.2025.101944_bib66","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00401-020-02132-y","article-title":"The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody","volume":"139","author":"Hoftberger","year":"2020","journal-title":"Acta Neuropathol."},{"issue":"1","key":"10.1016\/j.smim.2025.101944_bib67","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12974-016-0717-1","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin","volume":"13","author":"Jarius","year":"2016","journal-title":"J. Neuroinflamm."},{"issue":"1","key":"10.1016\/j.smim.2025.101944_bib68","article-title":"Antibodies to MOG have a demyelination phenotype and affect oligodendrocyte cytoskeleton","volume":"1","author":"Dale","year":"2014","journal-title":"Neurol. (R. ) Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.smim.2025.101944_bib69","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00401-021-02286-3","article-title":"Antibodies to MOG in CSF only: pathological findings support the diagnostic value","volume":"141","author":"Carta","year":"2021","journal-title":"Acta Neuropathol."},{"issue":"3","key":"10.1016\/j.smim.2025.101944_bib70","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000335","article-title":"ADEM-like presentation, anti-MOG antibodies, and MS pathology: TWO case reports","volume":"4","author":"K\u00f6rtv\u00e9lyessy","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"1","key":"10.1016\/j.smim.2025.101944_bib71","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/ana.26931","article-title":"Diagnostic utility of MOG antibody testing in cerebrospinal fluid","volume":"96","author":"Redenbaugh","year":"2024","journal-title":"Ann. Neurol."},{"issue":"9","key":"10.1016\/j.smim.2025.101944_bib72","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1002\/acn3.52163","article-title":"The clinical relevance of MOG antibody testing in cerebrospinal fluid","volume":"11","author":"Reynolds","year":"2024","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"6","key":"10.1016\/j.smim.2025.101944_bib73","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1001\/jamaneurol.2021.0912","article-title":"Positive predictive value of myelin oligodendrocyte glycoprotein autoantibody testing","volume":"78","author":"Sechi","year":"2021","journal-title":"JAMA Neurol."},{"issue":"2","key":"10.1016\/j.smim.2025.101944_bib74","first-page":"555","article-title":"The demyelinating potential of antibodies to myelin oligodendrocyte glycoprotein is related to their ability to fix complement","volume":"143","author":"Piddlesden","year":"1993","journal-title":"Am. J. Pathol."},{"issue":"2","key":"10.1016\/j.smim.2025.101944_bib75","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0165-5728(91)90014-X","article-title":"Antibodies to myelin-oligodendrocyte glycoprotein in cerebrospinal fluid from patients with multiple sclerosis and controls","volume":"31","author":"Xiao","year":"1991","journal-title":"J. Neuroimmunol."},{"issue":"1","key":"10.1016\/j.smim.2025.101944_bib76","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1084\/jem.188.1.169","article-title":"B lymphocytes producing demyelinating autoantibodies: development and function in gene-targeted transgenic mice","volume":"188","author":"Litzenburger","year":"1998","journal-title":"J. Exp. Med"},{"issue":"2","key":"10.1016\/j.smim.2025.101944_bib77","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/ana.25291","article-title":"Pathogenicity of human antibodies against myelin oligodendrocyte glycoprotein","volume":"84","author":"Spadaro","year":"2018","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.smim.2025.101944_bib78","article-title":"More efficient complement activation by anti-aquaporin-4 compared with anti-myelin oligodendrocyte glycoprotein antibodies","volume":"10","author":"Lerch","year":"2023","journal-title":"Neurol.: Neuroimmunol. Neuroinflamm."},{"issue":"11","key":"10.1016\/j.smim.2025.101944_bib79","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.165373","article-title":"MOGAD patient autoantibodies induce complement, phagocytosis, and cellular cytotoxicity","volume":"8","author":"Yandamuri","year":"2023","journal-title":"JCI Insight"},{"issue":"13","key":"10.1016\/j.smim.2025.101944_bib80","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2300648120","article-title":"Dissection of complement and Fc-receptor-mediated pathomechanisms of autoantibodies to myelin oligodendrocyte glycoprotein","volume":"120","author":"Mader","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.smim.2025.101944_bib81","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG Subclasses and Allotypes: From Structure to Effector Functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.smim.2025.101944_bib82","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1001\/archneur.65.7.913","article-title":"Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis","volume":"65","author":"Waters","year":"2008","journal-title":"Arch. Neurol."},{"issue":"18","key":"10.1016\/j.smim.2025.101944_bib83","doi-asserted-by":"crossref","first-page":"16516","DOI":"10.1074\/jbc.M111.227298","article-title":"Binding affinity and specificity of neuromyelitis optica autoantibodies to aquaporin-4 M1\/M23 isoforms and orthogonal arrays","volume":"286","author":"Crane","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.smim.2025.101944_bib84","article-title":"Different complement activation patterns following C5 cleavage in MOGAD and AQP4-IgG+NMOSD","volume":"11","author":"Kaneko","year":"2024","journal-title":"Neurol. Neuroimmunol. amp; Neuroinflamm."},{"key":"10.1016\/j.smim.2025.101944_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577699","article-title":"C3 and C4 complement levels in AQP4-IgG-positive NMOSD and in MOGAD","volume":"360","author":"Pache","year":"2021","journal-title":"J. Neuroimmunol."},{"issue":"6","key":"10.1016\/j.smim.2025.101944_bib86","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/ana.26226","article-title":"Complement activation is a prominent feature of MOGAD","volume":"90","author":"Keller","year":"2021","journal-title":"Ann. Neurol."},{"issue":"7","key":"10.1016\/j.smim.2025.101944_bib87","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1177\/1352458516669002","article-title":"Plasma complement biomarkers distinguish multiple sclerosis and neuromyelitis optica spectrum disorder","volume":"23","author":"Hakobyan","year":"2017","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.smim.2025.101944_bib88","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jneuroim.2015.10.002","article-title":"Increased interleukin-6 correlates with myelin oligodendrocyte glycoprotein antibodies in pediatric monophasic demyelinating diseases and multiple sclerosis","volume":"289","author":"Horellou","year":"2015","journal-title":"J. Neuroimmunol."},{"issue":"3","key":"10.1016\/j.smim.2025.101944_bib89","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/acn3.164","article-title":"Histopathology and clinical course of MOG-antibody-associated encephalomyelitis","volume":"2","author":"Spadaro","year":"2015","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"12","key":"10.1016\/j.smim.2025.101944_bib90","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1177\/1352458515622986","article-title":"Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in 'pattern II multiple sclerosis' and brain biopsy findings in a MOG-IgG-positive case","volume":"22","author":"Jarius","year":"2016","journal-title":"Mult. Scler."},{"issue":"5","key":"10.1016\/j.smim.2025.101944_bib91","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/brain\/awaa102","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study","volume":"143","author":"Takai","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.smim.2025.101944_bib92","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.679770","article-title":"Regulatory T cells increase after rh-MOG stimulation in non-relapsing but decrease in relapsing MOG antibody-associated disease at onset in children","volume":"12","author":"Horellou","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.smim.2025.101944_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2023.109734","article-title":"The immune imbalance between follicular regulatory and helper T cells in myelin oligodendrocyte glycoprotein IgG-associated disease","volume":"255","author":"Chang","year":"2023","journal-title":"Clin. Immunol."},{"issue":"2","key":"10.1016\/j.smim.2025.101944_bib94","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0149411","article-title":"B Cell, Th17, and neutrophil related cerebrospinal fluid cytokine\/chemokines are elevated in MOG antibody associated demyelination","volume":"11","author":"Kothur","year":"2016","journal-title":"PloS One"},{"issue":"9","key":"10.1016\/j.smim.2025.101944_bib95","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1136\/jnnp-2018-317969","article-title":"CSF cytokine profile in MOG-IgG+\u2009neurological disease is similar to AQP4-IgG+\u2009NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications","volume":"89","author":"Kaneko","year":"2018","journal-title":"J. Neurol., Neurosurg. amp;amp; Psychiatry"},{"issue":"6","key":"10.1016\/j.smim.2025.101944_bib96","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.4049\/jimmunol.132.6.2948","article-title":"Isolation and characterization of B cell differentiation factor (BCDF) secreted from a human B lymphoblastoid cell line","volume":"132","author":"Yoshizaki","year":"1984","journal-title":"J. Immunol."},{"issue":"6469","key":"10.1016\/j.smim.2025.101944_bib97","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/368339a0","article-title":"Impaired immune and acute-phase responses in interleukin-6-deficient mice","volume":"368","author":"Kopf","year":"1994","journal-title":"Nature"},{"issue":"7090","key":"10.1016\/j.smim.2025.101944_bib98","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature04753","article-title":"Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells","volume":"441","author":"Bettelli","year":"2006","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.smim.2025.101944_bib99","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1172\/JCI113921","article-title":"Synovium as a source of interleukin 6 in vitro. Contribution to local and systemic manifestations of arthritis","volume":"83","author":"Guerne","year":"1989","journal-title":"J. Clin. Invest"},{"issue":"1","key":"10.1016\/j.smim.2025.101944_bib100","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1161\/01.CIR.100.1.55","article-title":"Interleukin-6 and RANTES in Takayasu arteritis: a guide for therapeutic decisions?","volume":"100","author":"Noris","year":"1999","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.smim.2025.101944_bib101","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3899\/jrheum.100717","article-title":"Tocilizumab for rheumatoid arthritis: a cochrane systematic review","volume":"38","author":"SINGH","year":"2011","journal-title":"J. Rheumatol."},{"issue":"3","key":"10.1016\/j.smim.2025.101944_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103275","article-title":"The effectiveness of tocilizumab and its comparison with tumor necrosis factor alpha inhibitors for Takayasu Arteritis: a systematic review and meta-analysis","volume":"22","author":"Misra","year":"2023","journal-title":"Autoimmun. Rev."},{"issue":"10","key":"10.1016\/j.smim.2025.101944_bib103","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1084\/jem.20071119","article-title":"GM-CSF mediates autoimmunity by enhancing IL-6-dependent Th17 cell development and survival","volume":"205","author":"Sonderegger","year":"2008","journal-title":"J. Exp. Med."},{"issue":"6","key":"10.1016\/j.smim.2025.101944_bib104","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/ni.2027","article-title":"ROR\u03b3t drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation","volume":"12","author":"Codarri","year":"2011","journal-title":"Nat. Immunol."},{"issue":"8","key":"10.1016\/j.smim.2025.101944_bib105","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s00296-016-3480-9","article-title":"Anti-IL-17 therapy in treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials","volume":"36","author":"Kunwar","year":"2016","journal-title":"Rheumatol. Int."},{"issue":"3 ement 1","key":"10.1016\/j.smim.2025.101944_bib106","first-page":"82","article-title":"Disease course and disability outcomes in MOG-antibody disease in the UK","volume":"23","author":"Jurynczyk","year":"2017","journal-title":"Mult. Scler. J."},{"issue":"11","key":"10.1016\/j.smim.2025.101944_bib107","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1136\/jnnp-2024-333463","article-title":"Oral corticosteroid dosage and taper duration at onset in myelin oligodendrocyte glycoprotein antibody-associated disease influences time to first relapse","volume":"95","author":"Trewin","year":"2024","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"11","key":"10.1016\/j.smim.2025.101944_bib108","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1001\/jamaneurol.2018.1814","article-title":"Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders","volume":"75","author":"Lopez-Chiriboga","year":"2018","journal-title":"JAMA Neurol."},{"issue":"9","key":"10.1016\/j.smim.2025.101944_bib109","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1212\/WNL.0000000000004312","article-title":"Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome","volume":"89","author":"Hennes","year":"2017","journal-title":"Neurology"},{"issue":"14","key":"10.1016\/j.smim.2025.101944_bib110","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1177\/1352458516631038","article-title":"Children with multiphasic disseminated encephalomyelitis and antibodies to the myelin oligodendrocyte glycoprotein (MOG): Extending the spectrum of MOG antibody positive diseases","volume":"22","author":"Baumann","year":"2016","journal-title":"Mult. Scler. (Houndmills, Basingstoke, Engl. )"},{"key":"10.1016\/j.smim.2025.101944_bib111","article-title":"Prognostic relevance of quantitative and longitudinal MOG antibody testing in patients with MOGAD: a multicentre retrospective study","author":"Gastaldi","year":"2022","journal-title":"J. Neurol., Neurosurg., Psychiatry"},{"key":"10.1016\/j.smim.2025.101944_bib112","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2023-332851","article-title":"The MOG antibody non-P42 epitope is predictive of a relapsing course in MOG antibody-associated disease","author":"Liyanage","year":"2024","journal-title":"J. Neurol., Neurosurg., Psychiatry"},{"key":"10.1016\/j.smim.2025.101944_bib113","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1200961","article-title":"Clinical characteristics of myelin oligodendrocyte glycoprotein antibody-associated disease according to their epitopes","volume":"14","author":"Seok","year":"2023","journal-title":"Front. Neurol."},{"issue":"7","key":"10.1016\/j.smim.2025.101944_bib114","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.4049\/jimmunol.1301296","article-title":"Distinction and temporal stability of conformational epitopes on myelin oligodendrocyte glycoprotein recognized by patients with different inflammatory central nervous system diseases","volume":"191","author":"Mayer","year":"2013","journal-title":"J. Immunol. (Baltim., Md.: 1950)"},{"key":"10.1016\/j.smim.2025.101944_bib115","article-title":"The MOG antibody non-P42 epitope is associated with a higher risk of relapse in paediatric MOGAD","author":"Aseel El Hajj","year":"2025","journal-title":"J. Neurol., Neurosurg., Psychiatry"},{"key":"10.1016\/j.smim.2025.101944_bib116","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104570","article-title":"Neutrophil to lymphocyte ratio may be a useful marker in distinguishing MOGAD and MS and platelet to lymphocyte ratio associated with MOGAD activity","volume":"71","author":"Lin","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.smim.2025.101944_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103253","article-title":"High titers of myelin oligodendrocyte glycoprotein antibody are only observed close to clinical events in pediatrics","volume":"56","author":"Lui","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.smim.2025.101944_bib118","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1136\/jnnp-2019-321988","article-title":"Peripheral blood helper T cell profiles and their clinical relevance in MOG-IgG-associated and AQP4-IgG-associated disorders and MS","volume":"91","author":"Liu","year":"2020","journal-title":"J. Neurol., Neurosurg., Psychiatry"},{"key":"10.1016\/j.smim.2025.101944_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102005","article-title":"Clinical and immunological differences between MOG associated disease and anti AQP4 antibody-positive neuromyelitis optica spectrum disorders: blood-brain barrier breakdown and peripheral plasmablasts","volume":"41","author":"Tanaka","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.smim.2025.101944_bib120","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104796","article-title":"Novel index, neutrophil percentage (%) is a useful marker for disease activity in MOG antibody-associated disease","volume":"76","author":"Baek","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.smim.2025.101944_bib121","doi-asserted-by":"crossref","first-page":"6481","DOI":"10.1038\/s41598-023-33827-3","article-title":"White blood cell count profiles in anti-aquaporin-4 antibody seropositive neuromyelitis optica spectrum disorder and anti-myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"13","author":"Akaishi","year":"2023","journal-title":"Sci. Rep. -uk"},{"key":"10.1016\/j.smim.2025.101944_bib122","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102345","article-title":"Neutrophil-to-lymphocyte ratio correlates with disease activity in myelin oligodendrocyte glycoprotein antibody associated disease (MOGAD) in children","volume":"45","author":"Benetou","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"12","key":"10.1016\/j.smim.2025.101944_bib123","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25126295","article-title":"Tau, Glial fibrillary acidic protein, and neurofilament light chain as brain protein biomarkers in cerebrospinal fluid and blood for diagnosis of neurobiological diseases","volume":"25","author":"Park","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.smim.2025.101944_bib124","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.647618","article-title":"Serum neurofilament light and GFAP are associated with disease severity in inflammatory disorders with aquaporin-4 or myelin oligodendrocyte glycoprotein antibodies","volume":"12","author":"Chang","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.smim.2025.101944_bib125","article-title":"Serum neurofilament light chain in adult and pediatric patients with myelin oligodendrocyte glycoprotein antibody-associated disease: correlation with relapses and seizures","author":"Luo","year":"2021","journal-title":"J. Neurochem."},{"issue":"10","key":"10.1016\/j.smim.2025.101944_bib126","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1177\/13524585221081090","article-title":"Serum neurofilament light-chain levels in children with monophasic myelin oligodendrocyte glycoprotein-associated disease, multiple sclerosis, and other acquired demyelinating syndrome","volume":"28","author":"Wendel","year":"2022","journal-title":"Mult. Scler."},{"key":"10.1016\/j.smim.2025.101944_bib127","article-title":"Absence of attack-independent neuroaxonal injury in MOG antibody-associated disease: Longitudinal assessment of serum neurofilament light chain","author":"Hyun","year":"2021","journal-title":"Mult. Scler."},{"key":"10.1016\/j.smim.2025.101944_bib128","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102833","article-title":"NfL levels predominantly increase at disease onset in MOG-Abs-associated disorders","volume":"50","author":"Mariotto","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.smim.2025.101944_bib129","article-title":"Serum biomarkers in myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"7","author":"Kim","year":"2020","journal-title":"Neurol. (R. ) Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.smim.2025.101944_bib130","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2020.577361","article-title":"Serum level of IL-1\u03b2 in patients with inflammatory demyelinating disease: Marked upregulation in the early acute phase of MOG antibody associated disease (MOGAD)","volume":"348","author":"Kwon","year":"2020","journal-title":"J. Neuroimmunol."},{"issue":"14","key":"10.1016\/j.smim.2025.101944_bib131","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1177\/13524585231200720","article-title":"Microfibrillar-associated protein 4 as a potential marker of acute relapse in inflammatory demyelinating diseases of the central nervous system: pathological and clinical aspects","volume":"29","author":"Samadzadeh","year":"2023","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.smim.2025.101944_bib132","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.908527","article-title":"High levels of cerebrospinal fluid soluble triggering receptor expressed on myeloid cells 2 might be a biomarker of activity in pediatric patients with MOG-AD","volume":"10","author":"Zhou","year":"2022","journal-title":"Front. Pediatr."},{"issue":"1","key":"10.1016\/j.smim.2025.101944_bib133","article-title":"Identification of TNFAIP3 as relapse biomarker and potential therapeutic target for MOG antibody associated diseases","volume":"10","author":"Saxena","year":"2020","journal-title":"Sci. Rep. -uk"},{"key":"10.1016\/j.smim.2025.101944_bib134","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.716195","article-title":"Evaluation of thiol homeostasis in multiple sclerosis and neuromyelitis optica spectrum disorders","volume":"12","author":"Arslan","year":"2021","journal-title":"Front. Neurol."},{"issue":"2","key":"10.1016\/j.smim.2025.101944_bib135","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s10072-023-07008-z","article-title":"The relationship between plasma prolactin levels and clinical manifestations with neuromyelitis optica spectrum disorders","volume":"45","author":"Liu","year":"2024","journal-title":"Neurol. Sci."},{"issue":"9","key":"10.1016\/j.smim.2025.101944_bib136","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1136\/jnnp-2022-330412","article-title":"Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder","volume":"94","author":"Aktas","year":"2023","journal-title":"J. Neurol., Neurosurg., Psychiatry"},{"issue":"12","key":"10.1016\/j.smim.2025.101944_bib137","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1007\/s00415-020-10026-y","article-title":"Treatment of MOG antibody associated disorders: results of an international survey","volume":"267","author":"Whittam","year":"2020","journal-title":"J. Neurol."},{"issue":"5","key":"10.1016\/j.smim.2025.101944_bib138","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/ene.13602","article-title":"Paediatric acute disseminated encephalomyelitis followed by optic neuritis: disease course, treatment response and outcome","volume":"25","author":"Wong","year":"2018","journal-title":"Eur. J. Neurol."},{"issue":"2","key":"10.1016\/j.smim.2025.101944_bib139","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","article-title":"Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination","volume":"89","author":"Ramanathan","year":"2018","journal-title":"J. Neurol., Neurosurg. amp;amp; Psychiatry"},{"issue":"9","key":"10.1016\/j.smim.2025.101944_bib140","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/S1474-4422(21)00218-0","article-title":"Myelin-oligodendrocyte glycoprotein antibody-associated disease","volume":"20","author":"Marignier","year":"2021","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.smim.2025.101944_bib141","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.autrev.2015.12.004","article-title":"Anti-MOG antibody: the history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination","volume":"15","author":"Ramanathan","year":"2016","journal-title":"Autoimmun. Rev."},{"issue":"1","key":"10.1016\/j.smim.2025.101944_bib142","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11940-019-0541-x","article-title":"Treatment approaches for MOG-Ab-associated demyelination in children","volume":"21","author":"Hacohen","year":"2019","journal-title":"Curr. Treat. Options Neurol."},{"key":"10.1016\/j.smim.2025.101944_bib143","article-title":"Apheresis therapies in MOGAD: a retrospective study of 117 therapeutic interventions in 571 attacks","author":"Schwake","year":"2024","journal-title":"J. Neurol., Neurosurg. amp; Psychiatry"},{"issue":"11","key":"10.1016\/j.smim.2025.101944_bib144","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s11940-023-00776-1","article-title":"Emerging principles for treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)","volume":"25","author":"Wolf","year":"2023","journal-title":"Curr. Treat. Options Neurol."},{"issue":"22","key":"10.1016\/j.smim.2025.101944_bib145","doi-asserted-by":"crossref","first-page":"E2504","DOI":"10.1212\/WNL.0000000000201260","article-title":"Long-term effectiveness and safety of rituximab in neuromyelitis optica spectrum disorder and MOG antibody disease","volume":"99","author":"Barreras","year":"2022","journal-title":"Neurology"},{"issue":"15 1","key":"10.1016\/j.smim.2025.101944_bib146","article-title":"Interleukin-6 inhibition with tocilizumab for relapsing MOG-IgG associated disorder","volume":"96","author":"Elsbernd","year":"2021","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.smim.2025.101944_bib147","article-title":"Neuromyelitis optica study, G., interleukin-6 receptor blockade in treatment-refractory MOG-IgG-associated disease and neuromyelitis optica spectrum disorders","volume":"9","author":"Ringelstein","year":"2022","journal-title":"Neurol. (R. ) Neuroimmunol. Neuroinflamm."}],"container-title":["Seminars in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044532325000168?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044532325000168?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T21:46:24Z","timestamp":1778795184000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044532325000168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":147,"alternative-id":["S1044532325000168"],"URL":"https:\/\/doi.org\/10.1016\/j.smim.2025.101944","relation":{},"ISSN":["1044-5323"],"issn-type":[{"value":"1044-5323","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Insights into pathogenesis and biomarkers of prognosis","name":"articletitle","label":"Article Title"},{"value":"Seminars in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.smim.2025.101944","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101944"}}